Interstitial Cystitis Market Growth Analysis, Segmentation, Size, Share, Trend, Future Demand and Leading Players Updates by Forecast to 2030 | Lipella Pharmaceuticals, Purdue Pharma, Alivio Therapeutics, Seikagaku Corporation, Kyorin Holdings and Many More

DelveInsight has launched a report on “Interstitial Cystitis – Market Insights, Epidemiology, and Market Forecast-2030”

DelveInsight’s “Interstitial Cystitis – Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Interstitial Cystitis, historical and forecasted epidemiology as well as the Interstitial Cystitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the Facts:

1. According to DelveInsight, the total prevalent population of Interstitial Cystitis in the Seven Major Markets was approximately 8,517,779 in 2017.
2. In the epidemiology model, the analystsreported a higher prevalence of Interstitial Cystitis the United States with around 5,000,101 prevalent cases in 2017.
3. Among the European countries, Germany had the highest prevalent population of Interstitial Cystitis with 844,367 cases.
4. Spain had the lowest prevalent population of 4,95,983 in 2017.

Key facts of the report:

1. Interstitial Cystitis market report covers a descriptive overview and comprehensive insight of the Interstitial Cystitis epidemiology and  Interstitial Cystitis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Interstitial Cystitis market report provides insights on the current and emerging therapies.
3. Interstitial Cystitis market report offers a global historical and forecasted market covering drug outreach in 7MM.
4. Interstitial Cystitis market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Interstitial Cystitis market.

Request for Sample Pages:  https://www.delveinsight.com/sample-request/interstitial-cystitis-market

“As per DelveInsight’s analysis, the estimates suggest higher prevalence of the disease among the females throughout the 7MM”

According to the Urology Care Foundation, Interstitial cystitis/bladder pain syndrome (BPS) is a chronic bladder health issue. It is a feeling of pain and pressure in the bladder area. Along with this pain occurs in the lower urinary tract, which last for more than 6 weeks, without having an infection or other clear causes. It is a chronic, or long-lasting condition that causes painful urinary symptoms.

According to Interstitial Cystitis Association, currently here are two recognized subtypes of Interstitial cystitis: Non ulcerative and Ulcerative.

The exact cause of the disease is not known, but there are certain theories, such as a defect in the bladder tissue, which may allow irritating substances in the urine to penetrate the bladder, a specific type of inflammatory cell, called a mast cell. This cell releases histamine and other chemicals that lead to IC/BPS symptoms, changes in the nerves that carry bladder sensations, so pain is caused by events that are generally not painful, the body’s immune system attacks the bladder which is similar to other autoimmune conditions.

The symptoms include pain in pelvis or between the vagina and anus in women, and between the scrotum and anus in men (perineum), along with chronic pelvic pain, a persistent, urgent need to urinate, frequent urination—often of small amounts—throughout the day and night (up to 60 times a day), pain or discomfort while the bladder fills, and relief after urinating.

Some of the key companies working on Interstitial Cystitis are:

• Lipella Pharmaceuticals
• Purdue Pharma/Alivio Therapeutics
• Seikagaku Corporation
• Kyorin Holdings

And Many Others.

The launch of the emerging therapies is expected to significantly impact the Interstitial Cystitis treatment scenario in the upcoming years:-

 Drugs Covered:

• LP-08
• ALV-107
• SI-722
• KRP-116D

And Many Others

Request for Sample Pages:  https://www.delveinsight.com/sample-request/interstitial-cystitis-market

Table of Contents:

1. Key Insights
2. Executive Summary of Interstitial Cystitis
3. Interstitial Cystitis: Market Overview at a Glance

3.1. Total Market Share (%) Distribution of Interstitial Cystitis in 2017

3.2. Total Market Share (%) Distribution of Interstitial Cystitis in 2030

1. Interstitial Cystitis (IC): Disease Background and Overview

4.1. Introduction

4.2. Causes

4.3. Risk Factors

4.4. Signs and Symptoms

4.5. Pathophysiology

4.6. Biomarkers for patients with interstitial cystitis

4.7. Diagnosis

4.7.1. Consensus panel recommendations for the evaluation and diagnosis of patients with suspected IC/PBS

4.7.2. American Urology Association diagnosis guideline

4.7.3. Society of Interstitial Cystitis of Japan (SICJ) diagnosis guideline

1. Epidemiology and Patient Population

5.1. Population and Forecast Parameters

5.2. Key Findings

5.3. 7MM Total Prevalent Patient Population of Interstitial Cystitis

5.4. 7MM Total Diagnosed Prevalent Patient Population of Interstitial Cystitis

1. Country Wise-Epidemiology of Interstitial Cystitis

6.1. United States

6.1.1. Assumptions and Rationale

6.1.2. Total Prevalent Population of Interstitial Cystitis in the United States

6.1.3. Sex-Specific Prevalent Population of Interstitial Cystitis in the United States

6.1.4. Total Diagnosed Prevalence of Interstitial Cystitis in the United States

6.1.5. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States

6.2. EU5 Countries

6.2.1. Assumptions and Rationale

6.2.2. Germany

6.2.2.1. Total Prevalent Population of Interstitial Cystitis in Germany

6.2.2.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Germany

6.2.2.3. Total Diagnosed Prevalence of Interstitial Cystitis in Germany

6.2.2.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany

6.2.3. France

6.2.3.1. Total Prevalent Population of Interstitial Cystitis in France

6.2.3.2. Sex-Specific Prevalent Population of Interstitial Cystitis in France

6.2.3.3. Total Diagnosed Prevalence of Interstitial Cystitis in France

6.2.3.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in France

6.2.4. Italy

6.2.4.1. Total Prevalent Population of Interstitial Cystitis in Italy

6.2.4.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Italy

6.2.4.3. Total Diagnosed Prevalence of Interstitial Cystitis in Italy

6.2.4.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy

6.2.5. Spain

6.2.5.1. Total Prevalent Population of Interstitial Cystitis in Spain

6.2.5.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Spain

6.2.5.3. Total Diagnosed Prevalence of Interstitial Cystitis in Spain

6.2.5.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain

6.2.6. United Kingdom

6.2.6.1. Total Prevalent Population of Interstitial Cystitis in the United Kingdom

6.2.6.2. Sex-Specific Prevalent Population of Interstitial Cystitis in the United Kingdom

6.2.6.3. Total Diagnosed Prevalence of Interstitial Cystitis in the United Kingdom

6.2.6.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom

6.3. Japan

6.3.1. Assumptions and Rationale

6.3.2. Total Prevalent Population of Interstitial Cystitis in Japan

6.3.3. Sex-Specific Prevalent Population of Interstitial Cystitis in Japan

6.3.4. Total Diagnosed Prevalence of Interstitial Cystitis in Japan

6.3.5. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan

1. Treatment Algorithm, Current Treatment, and Medical Practices

7.1. Treatment

7.2. Treatment Algorithm

7.2.1. United States

7.2.2. Japan

7.2.3. Europe

1. Unmet Needs
2. Marketed Drugs

9.1. Elmiron: Janssen Pharmaceutical

9.1.1. Drug Description

9.1.2. Mechanism of action

9.1.3. Regulatory Milestones

9.1.4. Advantages & Disadvantages

9.1.5. Safety and Efficacy

9.1.6. Product Profile

1. Instillations

10.1. RIMSO-50: Mylan Pharmaceutical

10.1.1. Drug Description

10.1.2. Mechanism of Action

10.1.3. Regulatory Milestones

10.1.4. Advantages & Disadvantages

10.1.5. Safety and Efficacy

10.1.6. Product Profile

10.2. Cystistat: Bioniche Life Sciences Inc

10.2.1. Drug Description

10.2.2. Mechanism of Action

10.2.3. Regulatory Milestones

10.2.4. Advantages & Disadvantages

10.2.5. Safety and Efficacy

10.2.6. Product Profile

10.3. Gepan instill: Pohl-Boskamp GmbH

10.3.1. Drug Description

10.3.2. Mechanism of Action

10.3.3. Advantages & Disadvantages

10.3.4. Safety and Efficacy

10.3.5. Product Profile

10.4. Uracyst: Stellar Pharmaceuticals

10.4.1. Drug Description

10.4.2. Regulatory Milestones

10.4.3. Advantages & Disadvantages

10.4.4. Safety and Efficacy

10.4.5. Product Profile

10.4.6. Drug Description

10.4.7. Advantages & Disadvantages

10.4.8. Safety and Efficacy

10.4.9. Product Profile

10.5. iAluRil: Aspire Pharma

10.5.1. Drug Description

10.5.2. Mechanism of Action

10.5.3. Advantages & Disadvantages

10.5.4. Safety and Efficacy

10.5.5. Product Profile

List to be continued in the report…

1. Emerging Therapies

11.1. Key Cross Competition

11.2. KRP-116D: Kyorin Holdings

11.2.1. Product Description

11.2.2. Other Developmental Activities

11.2.3. Clinical Development

11.2.4. Safety and Efficacy

11.2.5. Advantages and Disadvantages

11.2.6. Product Profile

11.3. SI-722: Seikagaku Corporation

11.3.1. Product Description

11.3.2. Clinical Development

11.3.3. Product Profile

11.4. LP-08: Lipella Pharmaceuticals

11.4.1. Product Description

11.4.2. Other Developmental Activities

11.4.3. Clinical Development

11.4.4. Safety and Efficacy

11.4.5. Product Profile

List to be continued in the report…

1. Interstitial Cystitis: 7 Major Market Analysis

12.1. Key Findings

12.2. Market Size of Interstitial Cystitis in 7MM

1. The United States Market Outlook

13.1. United States Market Size

13.1.1. Total Market size of Interstitial Cystitis in the United States

13.1.2. Market Size by Current Therapies in the United States

13.1.3. Market Size by Emerging Therapies in the United States

1. EU-5 Countries: Market Outlook

14.1. Germany

14.1.1. Total Market size of Interstitial Cystitis in Germany

14.1.2. Market Size by Current Therapies in Germany

14.1.3. Market Size by Emerging Therapies in Germany

14.2. France

14.2.1. Total Market size of Interstitial Cystitis in France

14.2.2. Market Size by Current Therapies in France

14.2.3. Market Size by Emerging Therapies in France

14.3. Italy

14.3.1. Total Market size of Interstitial Cystitis in Italy

14.3.2. Market Size by Current Therapies in Italy

14.3.3. Market Size by Emerging Therapies in Italy

14.4. Spain

14.4.1. Total Market Size of Interstitial Cystitis in Spain

14.4.2. Market Size by Current Therapies in Spain

14.4.3. Market Size by Emerging Therapies in Spain

14.5. United Kingdom

14.5.1. Total Market size of Interstitial Cystitis in the United Kingdom

14.5.2. Market Size by Current Therapies in the United Kingdom

14.5.3. Market Size by Emerging Therapies in the United Kingdom

1. Japan: Market Outlook

15.1. Total Market size of Interstitial Cystitis in Japan

15.2. Market Size by Current Therapies in Japan

15.3. Market Size by Emerging Therapies in Japan

1. Access and Reimbursement
2. Market Drivers
3. Market Barriers
4. SWOT Analysis
5. Appendix

20.1. Report Methodology

1. DelveInsight Capabilities
2. Disclaimer
3. About DelveInsight

Related Reports:

 Interstitial Cystitis – Pipeline Insights, 2020

The Interstitial Cystitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Interstitial Cystitis across the complete product development cycle, including all clinical and nonclinical stages.

 Interstitial Cystitis – Epidemiology Forecast to 2030

The Interstitial Cystitis epidemiology covered in the report provides historical as well as forecasted Interstitial Cystitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.